USA – Koya Medical, an Oakland, Calif.-based healthcare company focused on advancing lymphatic and venous care through a comprehensive suite of people-centric platforms, closed a $26m Series B financing.
The round was led by 3×5 Partners, along with new investors including Asahi Kasei Ventures, Cadence Healthcare Ventures, and existing investors Arboretum Ventures and Scientific Health Development, among others.Proceeds from the financing will be used to accelerate the expansion and commercialization of its Dayspring® active compression system and to continue to advance the Dayspring platform and clinical research programs to pursue additional indications for lymphedema and venous disorders.Led by Andy Doraiswamy, Ph.D., founder, president, and CEO, Koya Medical is a healthcare company developing breakthrough treatments for lymphedema and venous diseases to increase movement, mobility, and personalized care. Dayspring is an active compression treatment that enables movement and mobility cleared by the U.S. Food and Drug Administration (FDA) to treat lymphedema and chronic venous conditions. It is a wearable and mobility-enabled active compression system that enables movement, mobility, and personalized care. The Dayspring system includes a low-profile active garment made of soft, breathable mesh using Koya’s proprietary Flexframe™ technology; a smart, rechargeable, hand-held controller that can be worn on a lanyard; and a mobile app that allows users or their clinicians to track therapy and program custom treatment options.Dayspring is FDA 510(k) cleared to treat lymphedema and other similar conditions that impact lymphatic flow in the upper and lower extremities.03/02/2022
